Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 1;153(4):e2023062850.
doi: 10.1542/peds.2023-062850.

A Communication and Decision-Making Framework for Pediatric Precision Medicine

Affiliations

A Communication and Decision-Making Framework for Pediatric Precision Medicine

Brittany L Greene et al. Pediatrics. .

Abstract

Advances in genomic testing have been pivotal in moving childhood cancer care forward, with genomic testing now a standard diagnostic tool for many children, adolescents, and young adults with cancer. Beyond oncology, the role of genomic testing in pediatric research and clinical care is growing, including for children with developmental differences, cardiac abnormalities, and epilepsy. Despite more standard use in their patients, pediatricians have limited guidance on how to communicate this complex information or how to engage parents in decisions related to precision medicine. Drawing from empirical work in pediatric informed consent and existing models of shared decision-making, we use pediatric precision cancer medicine as a case study to propose a conceptual framework to approach communication and decision-making about genomic testing in pediatrics. The framework relies on identifying the type of genomic testing, its intended role, and its anticipated implications to inform the scope of information delivered and the parents' role in decision-making (leading to shared decision-making along a continuum from clinician-guided to parent-guided). This type of framework rests on practices known to be standard in other complex decision-making but also integrates unique features of genomic testing and precision medicine. With the increasing prominence of genomics and precision medicine in pediatrics, with our communication and decision-making framework, we aim to guide clinicians to better support their pediatric patients and their parents in making informed, goal-concordant decisions throughout their care trajectory.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES: Dr Marron has received honoraria from Partner Therapeutics for serving on their Ethics Advisory Board and from Sanofi-Genzyme Global Oncology for delivering a lecture to their employees and holds stock in ROMTech. None of these entities has had a role in this work. Drs Lee and Rosenberg have indicated they have no potential conflicts of interest relevant to this article to disclose.

Figures

FIGURE 1
FIGURE 1
Four-step framework for SDM in pediatrics. This algorithm can be used for any discrete clinical decision. The first 3 steps each pose a question to the physician, and Steps 3 and 4 direct the type and version of SDM to use for the particular clinical decision. Adapted from “A 4-Step Framework for Shared Decision-making in Pediatrics” by D. Opel.
FIGURE 2
FIGURE 2
Framework for SDM in pediatric precision medicine. The type of genomic testing should inform the scope of the parent’s role in decision-making. As explained in greater detail in the text, testing that immediately impacts the child’s treatment and has a limited possibility of secondary or incidental findings is most amenable to clinician-guided SDM, whereas those without any impact on the child’s treatment but with a high likelihood of secondary or incidental findings are a better fit for parent-guided SDM (with many decisions lying somewhere between those 2 extremes).
FIGURE 3
FIGURE 3
Conceptual model of the SDM process in pediatric precision medicine. Decisions regarding genomic testing take place in a communication climate informed by the characteristics and perspectives of the clinician and parent engaged in the SDM process.

References

    1. Forrest SJ, Geoerger B, Janeway KA. Precision medicine in pediatric oncology. Curr Opin Pediatr. 2018;30(1):17–24 - PMC - PubMed
    1. Mody RJ, Prensner JR, Everett J, et al. . Precision medicine in pediatric oncology: lessons learned and next steps. Pediatr Blood Cancer. 2017;64(3):10.1002/pbc.26288 - PMC - PubMed
    1. Ahmed AA, Vundamati DS, Farooqi MS, Guest E. Precision medicine in pediatric cancer: current applications and future prospects. High Throughput. 2018;7(4):39. - PMC - PubMed
    1. Trautmann M, Hartmann W. Molecular approaches to diagnosis in Ewing sarcoma: fluorescence in situ hybridization (FISH). Methods Mol Biol. 2021;2226:65–83 - PubMed
    1. Hiemenz MC, Oberley MJ, Doan A, et al. . A multimodal genomics approach to diagnostic evaluation of pediatric hematologic malignancies. Cancer Genet. 2021;254–255:25–33 - PubMed